Anderson, I. M., Nutt, D. J., Deakin, J. F. W.
et al (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 14, 3–20.
Aronson, R., Offman, H. J., Joffe, R. T.
et al (1996) Triiodothyronine augmentation in the treatment of refractory depression. Archives of General Psychiatry, 53, 842–848.
Artigas, F., Celada, P., Laruelle, M.
et al (2001) How does pindolol improve antidepressant action?
Trends in Pharmacological Sciences, 22, 224–228.
Barbui, C. & Hotopf, M. (2001) Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry, 178, 129–144.
Barker, W. A., Scott, J. & Eccelston, D. (1987) The Newcastle Chronic Depression Study: results of a treatment regime. International Clinical Psychopharmacology, 2, 261–272.
Bauer, M. & Döpfmer, S. (1999) Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology, 19, 427–434.
Bauer, M. S. & Whybrow, P. C. (1990) Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study. Archives of General Psychiatry, 47, 435–440.
Bauer, M., Hellweg, R., Graf, K-J.
et al (1998) Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology, 18, 444–455.
Carpenter, L. L., Yasmin, S. & Price, L. H. (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry, 51, 183–188.
Cowen, P. J. (1998) Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment, 4, 320–327.
de Montigny, C., Silverstone, P. H., Debonnel, C.
et al (1999) Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. Journal of Clinical Pharmacology, 19, 401–406.
Fava, M. (2000) New approaches to the treatment of refractory depression. Journal of Clinical Psychiatry, 61 (suppl.1), 26–32.
Fava, M., Rosenbaum, J. F., McGrath, P. J.
et al (1994) Lithium and tricyclic augmentation of fluoxetine treatment for major depression: a double-blind controlled study. American Journal of Psychiatry, 151, 1372–1374.
Fava, G. A., Fabbri, S. & Sonino, N. (2002) Residual symptoms in depression: an emerging therapeutic target. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 1019–1027.
Frangou, S. (2005) Advancing the pharmacological treatment of bipolar depression. Advances in Psychiatric Treatment, 11, 28–37.
Goodwin, G. M. (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 17, 149–173.
Goodwin, G. M., Bowden, C. L., Calabrese, J. R.
et al (2004) A pooled analysis of 2 placebo-controlled 18 month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry, 65, 432–441.
Gournay, K. (2005) The changing face of psychiatric nursing. Revisiting: Mental Health Nursing. Advances in Psychiatric Treatment, 11, 6–11.
Hale, A. S., Procter, A. W. & Bridges, P. K. (1987) Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. British Journal of Psychiatry, 151, 213–217
Himmelhoch, J. M., Thase, M. E., Mallinger, A. G.
et al (1991) Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry, 148, 910–916
Hurowitz, G. I. & Liebowitz, M. R. (1993) Antidepressant-induced rapid cycling: six case reports. Journal of Clinical Psychopharmacology, 13, 52–56
Joffe, R. T., Singer, W., Levitt, A. J.
et al (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry, 50, 387–393.
Kennedy, N. & Paykel, E. S. (2004) Treatment and response in refractory depression: results from a specialist affective disorders service. Journal of Affective Disorders, 81, 49–53.
Licht, R. W. & Qvitzau, S. (2002) Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomized study of extended duration of treatment, dose increase or mianserin augmentation. Pharmacology, 161, 143–151
Marek, G. J., Carpenter, L. l., McDougle, C. J.
et al (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology, 28, 402–412.
Mueller, T. J., Keller, M. B., Leon, A. C.
et al (1996) Recovery after 5 years of unremitting major depressive disorder. Archives of General Psychiatry, 53, 794–799.
Muller-Siecheneder, F., Muller, M. J., Hillert, A.
et al (1998) Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. Journal of Clinical Psychopharmacology, 18, 111–120.
Nelson, J. C. (2003) Managing treatment-resistant major depression. Journal of Clinical Psychiatry, 64 (suppl. 1), 5–12.
Nemets, B., Stahl, Z. & Belmaker, R. H. (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry, 159, 477–479.
Nolen, W. A., Van de Putte, J. J., Dijken, W. A.
et al (1988) Treatment strategy in depression. II. MAO Inhibitors in depression resistant tricyclic antidepressants: two controlled cross-over studies with tranylcypromine versus 1–5 hydroxytryptophan and nomifensine. Acta Psychiatrica Scandinavica, 78, 676–683.
Perez, V., Soler, J., Puigdemont, D.
et al (1999) A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Archives of General Psychiatry, 56, 375–379
Price, L. H., Charney, D. S. & Heninger, G. R. (1985) Efficacy of lithium-tranylcypromine treatment in refractory depression. American Journal of Psychiatry, 142, 619–623.
Prudic, J., Sackeim, H. A. & Devenand, D. P. (1990) Medication resistance and clinical response to electro-convulsive therapy. Psychiatric Research, 31
Ostroff, R. B. & Nelson, J. C. (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry, 60, 256–259.
Quitkin, F. M., McGrath, P. J., Stewart, J. W.
et al (1989) Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Archives of General Psychiatry, 46, 787–793.
Rabiner, E. A., Bhagwagar, Z., Gunn, R. N.
et al (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET Evidence that the dose used in clinical trials is too low. American Journal of Psychiatry, 158, 2080–2082.
Rush, A. J., Fava, M., Wisniewski, S. R.
et al (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Controlled Clinical Trials, 25, 119–42
Sackheim, H. A., Prudic, J., Devenand, D. P.
et al (1990) The impact of medication resistance and continuation of pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. Journal of Clinical Psychopharmacology, 10, 96–104.
Schatzberg, A. F. (2003) New approaches to managing psychotic depression. Journal of Clinical Psychiatry, 64 (suppl. 1), 19–23.
Shelton, R. C., Tollefson, G. D., Tohen, M.
et al (2001) A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry, 158, 131–134.
Slutsker, L., Hoesly, F. C., Miller, L.
et al (1990) Eosinophiliamyalgia syndrome associated with exposure to tryptophan from a single manufacturer. Journal of the American Medical Association, 264, 213–217.
Smith, D., Dempster, C., Glanville, J.
et al (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry, 180, 396–404
Spiker, D. G., Weiss, J. C. & Dealy, R. S. (1985) The pharmacological treatment of delusional depression. American Journal of Psychiatry, 142, 430–436.
Taylor, D., Paton, C. & Kerwin, R. (2003) The South London and Maudsley NHS Trust 2003 Prescribing Guideline (7th edn), pp. 143–147. London: Martin Dunitz.
Thase, M. E. & Rush, A. J. (1997) When at first you don't succeed: sequential strategies for antidepressant non-responders. Journal of Clinical Psychiatry, 58 (suppl. 13), 23–29.
Thase, M. E., Friedman, E. S. & Howland, R. H. (2001) Management of treatment-resistant depression: psycho-therapeutic perspectives. Journal of Clinical Psychiatry, 62 (suppl. 18), 18–24.
Tohen, M., Vieta, E., Calabrese, J.
et al (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry, 60, 1079–1088.
Trivedi, M. H., Rush, A. J., Crismon, M. L.
et al (2004). Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Archives of General Psychiatry, 61, 669–680
Tyrer, P. & Murphy, S. (1990) Efficacy of combined antidepressant therapy in resistant neurotic disorder. British Journal of Psychiatry, 156, 115–118.